Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Infusion of Anti-MART-1 F5 TCR-Gene-Engineered Lymphocytes

NCT00509288 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

Melanoma
Skin Cancer

Interventions

BIOLOGICAL: autologous anti-MART-1 F5 T-cell receptor
DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Aldesleukin
BIOLOGICAL: autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes

Sponsor

National Cancer Institute (NCI)